Unknown

Dataset Information

0

In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.


ABSTRACT: INTRODUCTION:Theileria equi, an etiologic agent of equine piroplasmosis, is a tick-transmitted hemoprotozoan of the phylum Apicomplexa. Recent outbreaks of piroplasmosis in the United States have renewed interest in safe and effective treatment options. Although imidocarb dipropionate (IMD) is the drug of choice for clearance of T. equi, adverse reactions and recently documented resistance support the need for alternative therapeutic strategies. The recently described bumped kinase inhibitors (BKIs) are a new class of compounds that could potentially be used as safe and effective alternatives to IMD. In an initial effort to evaluate this potential, herein we determined the T. equi growth inhibitory activity of 11 BKIs relative to that of IMD and the previously tested BKI 1294. Because some BKIs have known human ether-à-go-go related gene (hERG) channel activity, we also assessed the hERG activity of each compound with the goal to identify those with the highest potency against T. equi coupled with the lowest potential for cardiotoxicity. RESULTS:Six BKIs inhibited T. equi growth in vitro, including the previously evaluated BKI 1294 which was used as a positive control. All six compounds were significantly less potent (higher 50% effective concentration (EC50)) than IMD. Two of those compounds were more potent than BKI 1294 control but had similar hERG activity. Although the remaining three compounds had similar to lower potency than BKI 1294, hERG EC50 was higher for three of them (BKI 1735, BKI 1369 and BKI 1318). CONCLUSIONS:The BKI compounds evaluated in this study inhibited T. equi in vitro and had diverse hERG activity. Based on these considerations, three compounds would be suitable for further evaluation. While these results provide a foundation for future work, in vivo pharmacokinetic, pharmacodynamics, and safety studies are needed before BKI compounds can be recommended for clinical use in T. equi infected horses.

SUBMITTER: Gimenez F 

PROVIDER: S-EPMC5959018 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.

Gimenez Fernanda F   Hines Siddra A SA   Evanoff Ryan R   Ojo Kayode K KK   Van Voorhis Wesley C WC   Maly Dustin J DJ   Vidadala Rama S R RSR   Mealey Robert H RH  

Veterinary parasitology 20180101


<h4>Introduction</h4>Theileria equi, an etiologic agent of equine piroplasmosis, is a tick-transmitted hemoprotozoan of the phylum Apicomplexa. Recent outbreaks of piroplasmosis in the United States have renewed interest in safe and effective treatment options. Although imidocarb dipropionate (IMD) is the drug of choice for clearance of T. equi, adverse reactions and recently documented resistance support the need for alternative therapeutic strategies. The recently described bumped kinase inhib  ...[more]

Similar Datasets

| S-EPMC5853794 | biostudies-literature
| S-EPMC5498274 | biostudies-literature
| S-EPMC3366411 | biostudies-literature
| PRJNA39115 | ENA
| S-EPMC5772984 | biostudies-literature
| S-EPMC6559944 | biostudies-literature
| S-EPMC3505731 | biostudies-literature
| S-EPMC6453670 | biostudies-literature
| S-EPMC4028807 | biostudies-literature